P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

Table 2 Inhibitory effect of SB-203580 on hyperalgesia in the Hargraeves model

COMPOUND	PAW WITHDRAWAL TIME PRE-DRUG TREATMENT (Seconds)	PAW WITHDRAWAL TIME POST-DRUG TREATMENT (Seconds)
Vehicle	10.7 ± 0.6	8.0 ± 0.8
Indomethacin (10 mg/kg)	11.1 ± 0.6	14.5 ± 0.6*
SB-203580 (30 mg/kg)	10.8 ± 0.9	12.2 ± 1.2*
SB-203580 (10 mg/kg)	11.1 ± 0.6	11.8 ± 1.4*
SB-203580 (3 mg/kg)	12.0 ± 0.7	10.9 ± 1.2*

The data are presented as the time for paw withdrawal from the heat source in seconds and are the mean ± S.E.M. from 10 rats per treatment group. The asterisk denotes a statistically significant difference (p < 0.05) between the vehicle and drug treatment groups.

ISSN: 1476-9255